Skip Navigation Links
SEARCH  



 
Bookmark and Share
CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)
CStone to out-license to EQRx exclusive rights to two late-stage immuno-oncology assets for development and commercialization outside of Greater China Agreement provides a pathway to bring CStone's sugemalimab (a...

Full "IntellAsia: Resources" article




Disclaimer | Terms Of Use And Privacy Statement


© Metals News. All rights reserved.